Pipeline
CV6 Therapeutics is building a pipeline of therapies designed to improve the effectiveness of cornerstone treatments in cancer and inflammatory diseases.
Our lead clinical asset, CV6-168, is engineered to work in combination with widely used therapies, enhancing their impact without adding toxicity. Additional programs extend this strategy into new disease areas.
Oncology
PROGRAM
DISCOVERY
PRECLINICAL
PHASE 1a
PHASE 1b
PHASE 2
CV6-168
NOVEL TARGETS
CV6-168
DISCOVERY
PRECLINICAL
PHASE 1a
PHASE 1b
PHASE 2
NOVEL TARGETS
DISCOVERY
PRECLINICAL
PHASE 1a
PHASE 1b
PHASE 2
Inflammatory Conditions
PROGRAM
DISCOVERY
PRECLINICAL
PHASE 1a
PHASE 1b
CV6-168
CV6-168
DISCOVERY
PRECLINICAL
PHASE 1a
PHASE 1b
Disclaimer: CV6-168 and CV6-1271 are investigational therapies that have not been approved for use outside clinical studies by the MHRA, FDA, or other regulatory authorities.